# EFfects of Y-6 SUblingual Tablets foR PaTients With AcUte Ischemic StRokE (FUTURE)

Study · id `cardio:ct-nct06138834` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06138834](<https://clinicaltrials.gov/study/NCT06138834>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06138834

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

## Technical summary

Registry record NCT06138834. Randomized; quadruple masking; primary purpose treatment. Start 2023-11 (anticipated); primary completion 2024-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT06138834, source copy `cardio:ctgov-nct06138834-2023-11-18`, retrieved 2026-10-26)
- Planned start: 2023-11 (anticipated) (ClinicalTrials.gov record NCT06138834, source copy `cardio:ctgov-nct06138834-2023-11-18`, retrieved 2026-10-26)
- Primary completion: 2024-11 (anticipated) (ClinicalTrials.gov record NCT06138834, source copy `cardio:ctgov-nct06138834-2023-11-18`, retrieved 2026-10-26)
- Completion: 2025-01 (anticipated) (ClinicalTrials.gov record NCT06138834, source copy `cardio:ctgov-nct06138834-2023-11-18`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06138834-2023-11-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: EFfects of Y-6 SUblingual Tablets foR PaTients With AcUte Ischemic StRokE (FUTURE)
- Condition: Acute Ischemic Stroke
- Condition: Large Vessel Occlusion
- Condition: Reperfusion
- Intervention (Drug): Low-dose Y-6 sublingual tablets
- Intervention (Drug): High-dose Y-6 sublingual tablets
- Intervention (Drug): Low-dose Cilostazol
- Intervention (Drug): High-dose Cilostazol
- Intervention (Drug): Placebo
- Lead sponsor: Beijing Tiantan Hospital
- Lead sponsor class: OTHER
- Collaborator: Neurodawn Pharmaceutical Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Beijing Tiantan Hospital (`cardio:org-beijing-tiantan-hospital`)
- Registry lists this organization as a collaborator: Neurodawn Pharmaceutical Co., Ltd. (`cardio:org-neurodawn-pharmaceutical-co-ltd`)

## Provenance

Content hash: 8a372a70a1a2d087050c2ab16dfa39d31c01da0f70228b09b83e39029d72b0f0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
